🔥🐔 BizChicken 🐔🔥
Companies Similar to Stoke Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Statera Biopharma, Inc.
STAT-201, Entolimod, STAT-401, STAT-205
Statera Bio Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat autoimmune diseases, cancers, and infectious diseases by rebalancing the immune system.
Symbol: STAB
Recent Price: $0.00
Industry: Biotechnology
CEO: Mr. Michael Kevin Handley
Sector: Healthcare
Employees: 46
Address: 2537 Research Boulevard, Fort Collins, CO 80526
Phone: 888 613 8802
Last updated: 2024-12-31
Sarepta Therapeutics, Inc.
EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.
Contact | About | Leadership | About | About | About | Locations | About | About | About | About
Symbol: SRPT
Recent Price: $121.19
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Sector: Healthcare
Employees: 1314
Address: 215 First Street, Cambridge, MA 02142
Phone: 617 274 4000
Leadership
- Douglas S. Ingram, President and Chief Executive Officer
- Bilal Arif, Executive Vice President, Chief Technical Operations Officer
- Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
- Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
- Ian M. Estepan, Executive Vice President, Chief Financial Officer
- Dallan Murray, Executive Vice President, Chief Customer Officer
- Alison Nasisi, Executive Vice President, Chief People Officer
- Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
- Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
- M. Kathleen Behrens, PhD, Chairwoman
- Richard J. Barry,
- Kathryn Boor, PhD,
- Michael Chambers,
- Deirdre Connelly,
- Stephen L. Mayo, PhD,
- Claude Nicaise, MD,
- Hans Wigzell, MD, PhD,
- John C. Martin, PhD (In Memoriam),
- Annemieke Aartsma-Rus, PhD,
- Carsten Bönnemann, MD,
- Joy Cavagnaro, PhD, DABT, Fellow ATS,
- Kay Davies, PhD, DBE FMedSci FRS,
- Steven Gray, PhD,
- Angela J. Russell, DPhil,
Last updated: 2024-12-31
Taysha Gene Therapies, Inc.
TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101
Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.
Symbol: TSHA
Recent Price: $1.73
Industry: Biotechnology
CEO: Mr. Sean P. Nolan
Sector: Healthcare
Employees: 52
Address: 3000 Pegasus Park Drive, Dallas, TX 75247
Phone: 214 612 0000
Last updated: 2024-12-31
Akebia Therapeutics, Inc.
Vadadustat
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease patients, with a lead product vadadustat for treating anemia due to chronic kidney disease.
Symbol: AKBA
Recent Price: $1.85
Industry: Biotechnology
CEO: Mr. John P. Butler MBA
Sector: Healthcare
Employees: 167
Address: 245 First Street, Cambridge, MA 02142
Phone: 617 871 2098
Last updated: 2024-12-31
Astria Therapeutics, Inc.
STAR-0215
Astria Therapeutics, Inc., is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic and immunological diseases in the United States. Its lead product candidate, STAR-0215, is targeting hereditary angioedema.
Symbol: ATXS
Recent Price: $8.88
Industry: Biotechnology
CEO: Ms. Jill C. Milne Ph.D.
Sector: Healthcare
Employees: 59
Address: 100 High Street, Boston, MA 02110
Phone: 617 349 1971
Last updated: 2024-12-31
Beam Therapeutics Inc.
precision genetic medicines
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.
About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About | About | Careers | About | Jobs | Careers
Symbol: BEAM
Recent Price: $25.28
Industry: Biotechnology
CEO: Mr. John M. Evans M.B.A.
Sector: Healthcare
Employees: 472
Address: 238 Main Street, Cambridge, MA 02142
Phone: 857 327 8775
Last updated: 2024-12-31
Compass Therapeutics, Inc.
CTX-009, CTX-471, CTX-8371
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.
Symbol: CMPX
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.
Sector: Healthcare
Employees: 32
Address: 80 Guest Street, Boston, MA 02135
Phone: 617 500 8099
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
4D Molecular Therapeutics, Inc.
4D-125, 4D-110, 4D-310, 4D-150, 4D-710
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.
About | About | Contact | News | News | News | Careers | Careers | About | DEI | Careers | Leadership | Careers | Careers
Symbol: FDMT
Recent Price: $5.30
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Sector: Healthcare
Employees: 201
Address: 5858 Horton Street, EmeryVille, CA 94608
Phone: 510 505 2680
Last updated: 2024-12-31
Generation Bio Co.
genetic medicines
Generation Bio Co. is a genetic medicines company developing therapies for rare and prevalent diseases, with a focus on the liver, retina, skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and is headquartered in Cambridge, Massachusetts.
Symbol: GBIO
Recent Price: $1.06
Industry: Biotechnology
CEO: Dr. Cameron Geoffrey McDonough M.D.
Sector: Healthcare
Employees: 174
Address: 301 Binney Street, Cambridge, MA 02142
Phone: 617 655 7500
Last updated: 2024-12-31
Lexeo Therapeutics, Inc. Common Stock
LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004
Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.
Symbol: LXEO
Recent Price: $6.54
Industry: Biotechnology
CEO: Mr. R. Nolan Townsend
Sector: Healthcare
Employees: 69
Address: 345 Park Avenue South, New York, null 10010
Phone: 212-547-9879
Last updated: 2024-12-31
Ocugen, Inc.
OCU400, OCU410, OCU200
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure blindness diseases. Its product pipeline includes gene therapy candidates targeting various retinal diseases and other conditions.
Symbol: OCGN
Recent Price: $0.81
Industry: Biotechnology
CEO: Dr. Shankar Musunuri M.B.A., Ph.D.
Sector: Healthcare
Employees: 65
Address: 263 Great Valley Parkway, Malvern, PA 19355
Phone: 484 328 4701
Last updated: 2024-12-31
PepGen Inc.
PGN-EDO51
Pep Gen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for neuromuscular and neurologic diseases. Its lead product, PGN-EDO51, is in Phase I trials for Duchenne muscular dystrophy.
Symbol: PEPG
Recent Price: $3.83
Industry: Biotechnology
CEO: Dr. James G. McArthur Ph.D.
Sector: Healthcare
Employees: 72
Address: 245 Main Street, Cambridge, MA 02142
Phone: 781-797-0979
Last updated: 2024-12-31
Rocket Pharmaceuticals, Inc.
Gene Therapies
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.
Symbol: RCKT
Recent Price: $12.03
Industry: Biotechnology
CEO: Dr. Gaurav D. Shah M.D.
Sector: Healthcare
Employees: 268
Address: 9 Cedarbrook Drive, Cranbury, NJ 08512
Phone: 609 659 8001
Last updated: 2024-12-31
Solid Biosciences Inc.
SGT-001
Solid Biosciences Inc. focuses on developing therapies for Duchenne muscular dystrophy, with lead product candidates like SGT-001 and SGT-003, and platform technologies like dual gene expression. The company is headquartered in Cambridge, Massachusetts, and collaborates with Ultragenyx Pharmaceutical Inc.
Vision/Values | Vision/Values | Vision/Values | About | Management | Directors | About | About | About | Culture | Benefits | About | Culture | Vision/Values | Contact | Contact | About | About
Symbol: SLDB
Recent Price: $4.07
Industry: Biotechnology
CEO: Mr. Alexander G. Cumbo
Sector: Healthcare
Employees: 88
Address: 141 Portland Street, Cambridge, MA 02139
Phone: 617 337 4680
Leadership
- Ian F. Smith, Chairman of the Board
- Bo Cumbo, President and CEO
- Martin Freed, M.D., F.A.C.P., Board Member
- Ilan Ganot, Co-Founder and Strategic Advisor to the CEO
- Clare Kahn, Ph.D., Board Member
- Georgia Keresty, Ph.D., M.PH., Board Member
- Sukumar Nagendran, M.D., President, Head of Research & Development, Taysha Gene Therapies
- Adam Stone, Chief Investment Officer of Perceptive Advisors
- Lynne Sullivan, Chief Financial Officer at Unity Biotechnology
Last updated: 2024-12-31
Shattuck Labs, Inc.
SL-172154
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States, with its lead product candidate being SL-172154.
About | About | News | About | Contact | Culture | Leadership | Leadership
Symbol: STTK
Recent Price: $1.17
Industry: Biotechnology
CEO: Dr. Taylor H. Schreiber M.D., Ph.D.
Sector: Healthcare
Employees: 75
Address: 500 West 5th Street, Austin, TX 78703
Phone: 512 900 4690
Last updated: 2024-12-31
Synlogic, Inc.
Synthetic Biotic Medicines
Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on the development of synthetic biotic medicines to treat metabolic and immunological diseases. The company's pipeline includes drug candidates for conditions such as phenylketonuria, homocystinuria, enteric hyperoxaluria, and solid tumors and lymphoma.
Symbol: SYBX
Recent Price: $1.40
Industry: Biotechnology
CEO: Mr. Antoine Awad
Sector: Healthcare
Employees: 6
Address: 301 Binney Street, Cambridge, MA 02142
Phone: 617 401 9975
Last updated: 2024-12-31
Verve Therapeutics, Inc.
VERVE-101
Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.
Symbol: VERV
Recent Price: $5.54
Industry: Biotechnology
CEO: Dr. Sekar Kathiresan M.D.
Sector: Healthcare
Employees: 255
Address: 500 Technology Square, Cambridge, MA 02139
Phone: 617 603 0070
Leadership
- Andrew Ashe, President, Chief Operating Officer and General Counsel
- Victoria Bartlett, Vice President, Program and Alliance Management
- Dan Balian, Associate Director, Supply Chain Management
- Allen Barrett, Director, Corporate Counsel
Last updated: 2024-12-31
Abeona Therapeutics Inc.
EB-101
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.
Symbol: ABEO
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.
Sector: Healthcare
Employees: 84
Address: 1330 Avenue of the Americas, New York, NY 10019
Phone: 646 813 4701
Last updated: 2024-12-31
Stoke Therapeutics, Inc.
STK-001, STK-002
Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.
Symbol: STOK
Recent Price: $10.80
Industry: Biotechnology
CEO: Dr. Edward M. Kaye M.D., Ph.D.
Sector: Healthcare
Employees: 110
Address: 45 Wiggins Avenue, Bedford, MA 01730
Phone: 781 430 8200
Leadership
- Edward M. Kaye, M.D., Chief Executive Officer & Director
- Jonathan Allan, J.D., General Counsel
- Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
- Jason Hoitt, Chief Commercial Officer
- Dawn Kalmar, Chief Communications Officer
- Tommy Leggett, Chief Financial Officer
- Shamim Ruff, Chief Regulatory Officer
- Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
- Joan Wood, Chief Human Resources Officer
- Adrian Krainer, Ph.D., Co-founder & Director
- Arthur Tzianabos, Ph.D., Chairman
- Jennifer Burstein, MBA, CPA, Director
- Seth L. Harrison, M.D., Director
- Arthur Levin, Ph.D., Director
- Garry E. Menzel, Ph.D., MBA, Director
- Ian F. Smith, Director
- Julie Anne Smith, Director
Last updated: 2024-12-31